Patient Engagement in Genomics Research Fuels Growth in Healthcare Segment

The global genomics market is set to expand from USD 47.07 billion in 2025 to USD 85.09 billion by 2030, with a CAGR of 12.6% ...
MedPage Today

TBI-Free Conditioning Before Transplant Effective in MRD-Negative B-ALL

A conditioning regimen free from total body irradiation (TBI) appeared to be just as effective as standard of care (SoC) in a ...
Yahoo Finance

Next Generation Sequencing (NGS) Market Poised to Hit $42.25 Billion by 2033: Key Drivers Behind the Surge - Latest Study by Grand View Research, Inc.

Technological innovation stands as a significant driver propelling the next-generation sequencing (NGS) market growth, with continuous advancements in sequencing platforms, such as whole genome ...

$46.5 Bn Next Generation Sequencing Market Industry Trends and Global Forecasts to 2035 by Type of Component, NGS Technique, Technology, Application Area, Targ…

The next generation sequencing market offers significant opportunities by enhancing the diagnosis and treatment of chronic ...
Nanowerk

Next-Generation Sequencing in Genomics and Clinical Research

This image illustrates the typical steps in next-generation sequencing (excluding single-molecule sequencing methods). The process begins with isolating genomic DNA (a) and breaking it into short ...
Cure Today

Next-Generation Sequencing Helps ‘Select the Best Treatment’ for Lung Cancer

Undergoing next-generation sequencing before receiving treatment can benefit patients with lung cancer and their doctors, as one expert told CURE®. For lung cancer, standard treatment regimens include ...
ascopubs.org

Clinical Utility of Tumor Next-Generation Sequencing Panel Testing to Inform Treatment Decisions for Patients With Advanced Solid Tumors in a Tertiary Care Center

Real-World Impact of an In-House Dihydropyrimidine Dehydrogenase (DPYD) Genotype Test on Fluoropyrimidine Dosing, Toxicities, and Hospitalizations at a Multisite Cancer Center Of the 582 surveys sent, ...
Targeted Oncology

TBI-Free Transplant Works for Younger Patients with B-ALL

The 2-year event-free survival (EFS) rate in the treatment arm was 76.3% (95% CI, 61.1%-86.1%), and the 2-year overall survival (OS) rate was 82.0% (95% CI, 67.1%-90.6%). These results showed that the ...